Extensively Hydrolyzed Formula Improves Allergic Symptoms in the Short Term in Infants with Suspected Cow’s Milk Protein Allergy

  • Michael J. Wilsey
    Department of Pediatrics, University of South Florida Morsani College of Medicine, Tampa, FL 33602, USA
  • Jared Florio
    Office of Medical Education, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL 33431, USA
  • Jesse Beacker
    Office of Medical Education, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL 33431, USA
  • Luke Lamos
    Office of Medical Education, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL 33431, USA
  • Jessica V. Baran
    Office of Medical Education, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL 33431, USA
  • Lea Oliveros
    Pediatric Gastroenterology, Hepatology, and Nutrition of Florida, St. Petersburg, FL 33701, USA
  • Panida Sriaroon
    Department of Pediatric Allergy and Immunology, University of South Florida Morsani College of Medicine, Tampa, FL 33602, USA
  • Jerry M. Brown
    Office of Medical Education, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL 33431, USA
  • Jon A. Vanderhoof
    Department of Gastroenterology Hepatology and Nutrition, Boys Town Hospital, Boys Town, NE 68010, USA

書誌事項

公開日
2023-03-30
権利情報
  • https://creativecommons.org/licenses/by/4.0/
DOI
  • 10.3390/nu15071677
公開者
MDPI AG

説明

<jats:p>Although extensively hydrolyzed formula is widely accepted for managing cow’s milk protein allergy (CMPA) long-term, there is a lack of evidence on its short-term efficacy. This study’s objective was to investigate the short-term symptom changes (within 3–6 weeks) of infants diagnosed with CMPA and managed with extensively hydrolyzed formula containing Lactobacillus rhamnosus at their subsequent physician visit. Healthcare providers treating 202 patients diagnosed with CMPA under six months old completed de-identified surveys, which were then analyzed in this prospective study. After their first visit, the patients were started on extensively hydrolyzed formula, and their baseline symptoms were scored on a severity scale of 0–3. Patients were then reevaluated at their next follow-up visit to assess changes in symptom severity. The study found statistically significant improvements in gastrointestinal (93%), skin (83%), respiratory (73%), and uncategorized symptoms (90%). These symptom improvements were consistent across different follow-up visit durations. This study is the largest prospective analysis conducted in the United States evaluating short-term change in CMPA symptoms severity in infants under six months old using extensively hydrolyzed formula. These findings suggest that extensively hydrolyzed formula is associated with clinical symptom relief, which is often noticeable by the next follow-up visit. However, additional randomized control trials are needed to validate these results.</jats:p>

収録刊行物

  • Nutrients

    Nutrients 15 (7), 1677-, 2023-03-30

    MDPI AG

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ